نبذة مختصرة : Introduction: Chronic Lymphoproliferative Diseases (DLPC) are a group of lymphatic neoplasms characterized by the proliferation of mature neoplastic lymphocytes. Immunophenotyping by Flow Cytometry (ICF) is a routine practice in the differential diagnosis of these tumors, contributing to greater precision. Objectives: To demonstrate the immunophenotypic profiles of patients with DLPC in Rio Grande do Norte (RN); Demonstrate the applicability of a specific panel for the diagnosis of patients with multiple myeloma; Determine the monoclonality of DLPC-B; Implement database for clinical research Methods: Patients (n = 500) with DLPC were investigated by CF. In addition, other patient information, such as age, sex and haematological data, was collected. Results: The results showed that 86.6% of the cases were DLPC-B and 13.4%, DLPC-T / NK. The distribution of DLPC-B was: 279 Chronic Lymphocytic Leukemia; Prolinfocytic Leukemia B; 11 Vilous Cell Leukemia; 3 Follicular lymphoma; 3 Splenic Lymphoma with Vilous Lymphocytes; 12 Mantle Cell Lymphoma; 01 Macroglobulinemia of Waldenstron; 47 Multiple Myeloma; 12 Plasma Cell Leukemia; 09 Burkitt's Lymphoma and 39 NHL-Leucemy. The DLPC classification of T / NK was: 11 Granular Lymphocyte Leukemia; 14 Prolinfocytic Leukemia T; 10 Adult T-Cell Leukemia; 8 Conclusions: The data demonstrate that immunophenotyping is a reliable and safe technique in the diagnostic clarification of patients with DLPC. It was possible to detect monoclonality in DLPC-B. Thediagnosis of multiple myeloma benefits from the specific panel application. This study consolidates as a clinical research base for DLPC in Rio Grande do Norte. Approved by ethics committee in research Hospital Onofre Lopes- UFRN ; Introdução: As Doenças Linfoproliferativas Crônicas (DLPC) constituem um grupo de neoplasias linfáticas que se caracterizam pela proliferação de linfócitos maduros neoplásicos. A Imunofenotipagem por Citometria de Fluxo (ICF) é uma prática de rotina no diagnóstico diferencial desses tumores, contribuindo ...
No Comments.